Article
Assessment of MLL methyltransferase gene expression in larynx carcinoma
Registro en:
FIGUEIREDO, D. L. A. et al. Assessment of MLL methyltransferase gene expression in larynx carcinoma. Oncology Reports, v. 33, p. 2017-2022, 2015.
1021-335X
10.3892/or.2015.3756
Autor
Figueiredo, David Livingstone Alves
Rabello, Doralina do Amaral
Zanette, Dalila Lucíola
Saggioro, Fabiano Pinto
Mamede, Rui Celso Martins
Zago, Marco Antonio
Silva, Wilson Araújo da
Araújo, Felipe Saldanha
Silva, Fabio Pittella
Resumen
Zanette, Dalila Luciola “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”. CNPq (National Council of Technological and Scientific Development) (no. 482869/2009-7
and 485868/2013-0); CAPES (Coordination for the Improvement of Higher Education Personnel) (no. 23038.007324/2011-16); and FAPDF (Federal District Research Foundation)
(no. 0193.000.495/2009). Larynx cancer is the second most common type of cancer among all head and neck cancers. Deregulation of epigenetic effectors, including altered expression of histone methyltransferases from the MLL (mixed lineage leukemia) family, have been reported in many cancer types, yet little is known concerning their involvement in larynx cancer. Our objective was to determine the expression profile of MLL genes in larynx carcinoma and normal adjacent tissues and correlate this profile to tumor characteristics. We analyzed the expression profile of 5 MLL genes in 13 cases of larynx carcinoma and their adjacent non-tumor tissues using quantitative real-time PCR. MLL3 was significantly downregulated in tumor samples compared to their normal counterparts, and all MLL genes showed decreased expression in advanced tumors compared to tumors in the initial stage. Altered expression in a single MLL gene was associated with a similar alteration in the other MLL genes, revealing a strong correlation of expression in each individual patient. In conclusion, MLL genes may have similar transcriptional control, and decreased expression of these genes may contribute to larynx cancer progression.